Literature DB >> 24921029

A primary care approach to myelodysplastic syndromes.

Djamshed Samiev1, Vijaya R Bhatt2, Joel D Armitage3, Lori J Maness2, Mojtaba Akhtari2.   

Abstract

Myelodysplastic syndromes (MDS) are probably the most common hematologic malignancies in adults over the age of 60 and are a major source of morbidity and mortality among older age groups. Diagnosis and management of this chronic blood cancer has evolved significantly in recent years and there are Food and Drug Administration-approved therapies that can extend patients' life expectancy and improve quality of life. Primary care physicians (PCPs) are often involved in the process of diagnosis and follow-up of MDS patients, especially those in low-risk groups. They can therefore play an important role in improving patient care and quality of life by ensuring early referral and participating in supportive management. There is also a shortage of oncologists which increases the importance of the role of PCPs in management of MDS patients. In the face of limited resources, PCPs can improve access and quality of care in MDS patients. This article provides an overview of the common manifestations, diagnostic approaches, and therapeutic modalities of MDS for PCPs, with a focus on when to suspect MDS, when a referral is appropriate, and how to provide appropriate supportive care for patients diagnosed with MDS.

Entities:  

Keywords:  Bone Marrow Diseases; Cytopenia; Myelodysplastic Syndromes; Primary Health Care

Year:  2014        PMID: 24921029      PMCID: PMC4040428          DOI: 10.4082/kjfm.2014.35.3.111

Source DB:  PubMed          Journal:  Korean J Fam Med        ISSN: 2005-6443


  28 in total

1.  International workshop on the relationship of prior therapy to balanced chromosome aberrations in therapy-related myelodysplastic syndromes and acute leukemia: overview report.

Authors:  Janet D Rowley; Harold J Olney
Journal:  Genes Chromosomes Cancer       Date:  2002-04       Impact factor: 5.006

2.  Recommendations for the transfusion of red blood cells.

Authors:  Giancarlo Liumbruno; Francesco Bennardello; Angela Lattanzio; Pierluigi Piccoli; Gina Rossetti
Journal:  Blood Transfus       Date:  2009-01       Impact factor: 3.443

3.  Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion.

Authors:  Alan List; Gordon Dewald; John Bennett; Aristotle Giagounidis; Azra Raza; Eric Feldman; Bayard Powell; Peter Greenberg; Deborah Thomas; Richard Stone; Craig Reeder; Kenton Wride; John Patin; Michele Schmidt; Jerome Zeldis; Robert Knight
Journal:  N Engl J Med       Date:  2006-10-05       Impact factor: 91.245

Review 4.  Myelodysplastic syndromes.

Authors:  Jiehao Zhou; Attilio Orazi; Magdalena B Czader
Journal:  Semin Diagn Pathol       Date:  2011-11       Impact factor: 3.464

Review 5.  Dysplasia has A differential diagnosis: distinguishing genuine myelodysplastic syndromes (MDS) from mimics, imitators, copycats and impostors.

Authors:  David P Steensma
Journal:  Curr Hematol Malig Rep       Date:  2012-12       Impact factor: 3.952

6.  Risk factors of myelodysplastic syndromes: a case-control study.

Authors:  S S Strom; Y Gu; S K Gruschkus; S A Pierce; E H Estey
Journal:  Leukemia       Date:  2005-11       Impact factor: 11.528

7.  Clinical and cytogenetic features of 508 Chinese patients with myelodysplastic syndrome and comparison with those in Western countries.

Authors:  B Chen; W-L Zhao; J Jin; Y-Q Xue; X Cheng; X-T Chen; J Cui; Z-M Chen; Q Cao; G Yang; Y Yao; H-L Xia; J-H Tong; J-M Li; J Chen; S-M Xiong; Z-X Shen; S Waxman; Z Chen; S-J Chen
Journal:  Leukemia       Date:  2005-05       Impact factor: 11.528

Review 8.  Evidence-based platelet transfusion guidelines.

Authors:  Sherrill J Slichter
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2007

Review 9.  Revisiting use of growth factors in myelodysplastic syndromes.

Authors:  Kam Newman; Lori Maness-Harris; Ihab El-Hemaidi; Mojtaba Akhtari
Journal:  Asian Pac J Cancer Prev       Date:  2012

10.  Myelodysplastic syndromes: incidence and survival in the United States.

Authors:  Xiaomei Ma; Monique Does; Azra Raza; Susan T Mayne
Journal:  Cancer       Date:  2007-04-15       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.